Insulin Aspart (NovoRapid / NovoLog)

1. Overview

Insulin aspart is a rapid-acting human insulin analog developed by Novo Nordisk and produced by recombinant DNA technology in Saccharomyces cerevisiae (baker's yeast). It is designed to mimic the physiological first-phase insulin response to meals by providing faster subcutaneous absorption and earlier peak activity than regular human insulin [1][2][15]. Insulin aspart was approved by the FDA on June 7, 2000, as NovoLog (marketed as NovoRapid outside the United States) and has become one of the most widely prescribed mealtime insulins worldwide for both type 1 and type 2 diabetes mellitus.

The molecule is a 51-amino acid, two-chain peptide (A-chain: 21 amino acids; B-chain: 30 amino acids) with the molecular formula C256H381N65O79S6 and a molecular weight of approximately 5825.8 Da [15][18]. It differs from native human insulin by a single amino acid substitution: proline at position B28 is replaced by aspartic acid (Asp-B28). This seemingly minor change was rationally designed based on the pioneering work of Brange et al. (1988), who demonstrated that the B28-B29 region of human insulin is critical for self-association into dimers and hexamers [1]. The introduction of a negatively charged aspartate residue at B28 disrupts the hydrophobic monomer-monomer contacts that stabilize dimer formation, resulting in markedly reduced self-association tendency and dramatically faster dissociation of hexamers into bioactive monomers after subcutaneous injection [1][2].

A second-generation formulation, faster-acting insulin aspart (marketed as Fiasp), was approved by the FDA on September 29, 2017. Fiasp contains the identical insulin aspart molecule reformulated with two additional excipients -- niacinamide (vitamin B3, which accelerates initial absorption) and L-arginine (which stabilizes the formulation) -- to achieve an even more rapid onset of appearance in plasma (approximately 2.5-5 minutes earlier) and greater early insulin exposure compared with standard insulin aspart [7][11][19]. Multiple biosimilar insulin aspart products have been approved, including insulin aspart-afrz (KIXELLE, Sanofi, 2023) [13], insulin aspart-szjj (Merilog, Gan & Lee, FDA-approved February 2025), and insulin aspart-xjhz (Kirsty, Sandoz, FDA-approved July 2025 as the first rapid-acting interchangeable biosimilar to NovoLog).

Molecular Weight

~5825.8 Da

Molecular Formula

C256H381N65O79S6

Structure

51 amino acids (A-chain 21 aa, B-chain 30 aa); two-chain disulfide-linked peptide

Key Modification

Pro-B28 to Asp-B28 substitution (aspartic acid replaces proline)

Onset of Action

10-20 min (NovoLog); 2.5-5 min faster (Fiasp)

Peak Effect

1-3 hours (NovoLog); 1-1.5 hours (Fiasp)

Duration of Action

3-5 hours

Bioavailability

~60-70% (subcutaneous)

Routes

Subcutaneous injection, IV infusion, CSII pump (approved)

FDA Status (NovoLog)

Approved June 7, 2000 (type 1 and type 2 diabetes)

FDA Status (Fiasp)

Approved September 29, 2017 (ultra-rapid mealtime insulin)

2. Mechanism of Action

Hexamer Dissociation and Rapid Absorption

The fundamental pharmacokinetic advantage of insulin aspart over regular human insulin derives entirely from its altered self-association behavior in the subcutaneous depot [1][2][15]. All commercial insulin formulations contain zinc, which promotes hexamer assembly for stability and shelf-life. When regular human insulin is injected subcutaneously, the hexameric form must first dissociate into dimers and then monomers before absorption into capillaries can occur -- a process requiring approximately 30-60 minutes. This delay is responsible for the slow onset (30-60 min), late peak (2-4 h), and prolonged tail (6-8 h) of regular insulin action, which poorly matches the rapid rise and fall of postprandial glucose.

In insulin aspart, the Asp-B28 substitution introduces electrostatic repulsion between adjacent monomers at the B28-B29 dimer-forming interface [1]. Specifically, the negatively charged carboxylate group of aspartate at B28 sterically and electrostatically clashes with neighboring monomers, reducing dimer affinity by approximately 6-fold and hexamer stability correspondingly. After subcutaneous injection, insulin aspart hexamers dissociate into monomers within minutes rather than the approximately 30 minutes required for regular insulin. Since only monomeric insulin is small enough (approximately 5.8 kDa) to be absorbed through fenestrated subcutaneous capillaries, the accelerated dissociation translates directly to faster absorption [2][15].

The resulting pharmacokinetic profile shows: onset of action in 10-20 minutes, peak plasma concentration at 40-50 minutes (versus approximately 80-120 minutes for regular insulin), and return to baseline within 3-5 hours (versus 6-8 hours for regular insulin) [2][11]. This profile more closely resembles the physiological first-phase insulin response to food intake.

Faster-Acting Insulin Aspart (Fiasp) -- Excipient-Enhanced Absorption

Fiasp achieves further acceleration of insulin aspart absorption through the addition of niacinamide (1.72 mg/mL) to the formulation [7][11][19]. Niacinamide promotes increased local vasodilation at the injection site, enhancing capillary blood flow and thereby accelerating the rate of monomer absorption into the systemic circulation. The result is approximately 5 minutes earlier appearance in plasma, approximately 50% greater insulin exposure in the first 30 minutes, and approximately 10 minutes earlier peak concentration compared with standard insulin aspart [11]. L-arginine (20 mg/mL) serves as a stabilizer to maintain formulation integrity. Importantly, the total bioavailability and overall glucose-lowering effect are equivalent; only the temporal profile is shifted earlier.

Insulin Receptor Signaling

Like native human insulin, insulin aspart binds to the insulin receptor (IR) on target cells with essentially identical affinity and activates the same downstream signaling cascades [17]. The Asp-B28 substitution is located in a region not involved in receptor binding (the receptor-binding surfaces involve A1-A3, A19-A21, B12, B16, B24-B26, and portions of the B-chain C-terminus). Consequently, insulin aspart retains full metabolic potency including stimulation of glucose transport via GLUT4 translocation, glycogen synthesis, suppression of hepatic gluconeogenesis, inhibition of lipolysis, and promotion of protein synthesis. The IGF-1 receptor binding affinity and mitogenic potency of insulin aspart are similar to those of human insulin [17].

3. Researched Applications

Mealtime Glycemic Control in Type 1 Diabetes (Strong Evidence -- FDA Approved)

The foundational clinical evidence for insulin aspart was established in a large multinational Phase 3 trial by Home et al. (2000), which randomized 1,070 adults with type 1 diabetes to insulin aspart or regular human insulin at mealtimes, both with NPH basal insulin [3]. Insulin aspart provided superior postprandial glucose control with a mean reduction in postprandial glucose increment of 19 mg/dL compared with regular insulin, while achieving similar overall HbA1c reduction. Total hypoglycemia rates were comparable, and patient satisfaction scores favored insulin aspart due to the convenience of injection immediately before meals rather than the 30-minute pre-meal injection required for regular insulin [3].

A Cochrane systematic review by Siebenhofer et al. (2006) pooling data from 49 RCTs of rapid-acting analogs (aspart, lispro, glulisine) versus regular human insulin confirmed a modest but consistent HbA1c advantage of approximately 0.1% with rapid-acting analogs, with clinically meaningful improvements in postprandial glucose control [12]. The benefit was most apparent in patients with type 1 diabetes on intensive basal-bolus therapy.

Type 2 Diabetes Mellitus (Strong Evidence -- FDA Approved)

Bretzel et al. (2004) demonstrated that insulin aspart at mealtimes with NPH insulin provided equivalent HbA1c reduction to regular human insulin in 423 adults with type 2 diabetes, with significantly better postprandial glucose profiles [4]. These findings supported the use of rapid-acting analogs in both type 1 and type 2 diabetes, though the incremental benefit over regular insulin is generally considered more meaningful in type 1 diabetes where tight postprandial control is more challenging.

Pregnancy (Strong Evidence)

The safety and efficacy of insulin aspart during pregnancy were established in a landmark trial by Mathiesen et al. (2007), which randomized 322 pregnant women with type 1 diabetes to insulin aspart or human insulin at mealtimes [5]. Insulin aspart was noninferior for HbA1c control, provided significantly lower postprandial glucose excursions, and was associated with 58% fewer severe hypoglycemic episodes (risk ratio 0.42, p=0.005). No adverse differences in perinatal outcomes, congenital malformations, or neonatal complications were observed. This trial established insulin aspart as safe and effective during pregnancy, leading to its inclusion in major guidelines for gestational diabetes management.

Continuous Subcutaneous Insulin Infusion (CSII) Pump Therapy (Strong Evidence)

Insulin aspart is widely used in insulin pump therapy. Bode et al. (2002) demonstrated in a double-blind crossover trial of 146 adults with type 1 diabetes that insulin aspart in CSII provided significantly better postprandial glucose control than buffered regular insulin, with comparable HbA1c and fewer catheter occlusion events [6]. The faster pharmacokinetic profile of insulin aspart is particularly advantageous in pump therapy, where only monomeric insulin is delivered (no hexameric depot), making the rapid onset even more relevant for precise mealtime bolus delivery.

Faster Aspart (Fiasp) -- The Onset Clinical Trial Program

The faster-acting formulation was evaluated in the comprehensive onset clinical trial program.

Onset 1 (n=1,143, type 1 diabetes) demonstrated that Fiasp was noninferior to standard aspart for HbA1c control, with statistically superior 1-hour postprandial glucose reduction (estimated treatment difference -12.0 mg/dL, p=0.0002) and 2-hour postprandial reduction (ETD -12.8 mg/dL, p=0.0006) [7].

Onset 2 (n=689, type 2 diabetes) confirmed noninferiority for overall glycemic control, with superior 1-hour postprandial glucose control (ETD -10.9 mg/dL, p=0.0036) [8].

Onset 3 evaluated Fiasp in CSII pump therapy (n=472, type 1 diabetes), demonstrating noninferiority to standard aspart for HbA1c with superior postprandial glucose control [9].

Onset 5 pediatric (n=777, children and adolescents ages 1-17 years) confirmed noninferiority and comparable safety across all pediatric age groups [10].

Comparison with Other Rapid-Acting Analogs

The three rapid-acting insulin analogs -- insulin aspart (NovoLog), insulin lispro (Humalog), and insulin glulisine (Apidris) -- have similar overall pharmacokinetic and pharmacodynamic profiles and are considered clinically interchangeable in most practice guidelines [12][15]:

• Insulin lispro: Lys-B28/Pro-B29 transposition. First rapid-acting analog (approved 1996). Very similar onset, peak, and duration to aspart. Extensive clinical experience
• Insulin aspart: Asp-B28 substitution. Approved 2000. Available in faster formulation (Fiasp)
• Insulin glulisine: Lys-B3/Glu-B29 substitution. Approved 2004. Zinc-free formulation

Head-to-head studies between these analogs have generally shown equivalent glycemic outcomes, and the Cochrane review confirmed no significant differences in HbA1c or hypoglycemia between the three agents [12].

4. Clinical Evidence Summary

5. Dosing in Research

Type 1 Diabetes (NovoLog). Insulin aspart should be injected subcutaneously 5-10 minutes before meals (or immediately before) as part of a basal-bolus regimen. The mealtime dose is individualized based on carbohydrate counting (typically 1 unit per 10-15 grams of carbohydrate, adjusted for insulin sensitivity). Total daily insulin is typically divided with approximately 40-50% as basal insulin and the remainder as mealtime bolus doses [18]. Injection sites include the abdomen (fastest absorption), anterior thigh, upper arm, or buttocks, with rotation to prevent lipodystrophy.

Type 2 Diabetes (NovoLog). Mealtime insulin aspart can be initiated at 4 units or approximately 10% of the basal dose at the largest meal, with titration by 1-2 units every 2-3 days to achieve postprandial glucose targets (generally 140-180 mg/dL at 1-2 hours post-meal) [18].

Fiasp Dosing. The same unit dosing as standard insulin aspart applies. The key difference is administration timing: Fiasp may be injected at the start of the meal or within 20 minutes after starting the meal, providing greater dosing flexibility [19].

CSII Pump Therapy. Insulin aspart or Fiasp is used in continuous subcutaneous infusion pumps with individualized basal rates and mealtime bolus doses. Infusion sets should be changed every 48-72 hours to minimize catheter occlusion and infection risk [6].

Intravenous Use. Insulin aspart can be administered intravenously under medical supervision for management of diabetic ketoacidosis and perioperative glucose control, with dose titrated by glucose monitoring [18].

6. Safety and Side Effects

The safety profile of insulin aspart is well-characterized across more than two decades of clinical use.

Hypoglycemia is the most important adverse effect, as with all insulin preparations. The risk is glucose-dependent and is influenced by dose, injection timing relative to meals, exercise, renal function, and concomitant medications. The rapid onset and shorter duration of action of insulin aspart compared with regular insulin may reduce the risk of late postprandial hypoglycemia, though overall hypoglycemia rates in clinical trials are generally comparable [3][12].

Injection-site reactions include lipodystrophy (lipohypertrophy more common than lipoatrophy) with repeated injections at the same site, and occasional local erythema, pruritus, or swelling. With Fiasp, injection-site reactions were modestly more frequent (2.9% vs 0.9% with standard aspart in onset 1), likely related to the niacinamide excipient causing local vasodilation and transient discomfort [7].

Weight gain may occur with insulin therapy as glycemic control improves and glucosuria decreases. Weight gain is generally modest (1-3 kg in the first year of insulin therapy) and is not specific to insulin aspart versus other insulin formulations.

Immunogenicity. Anti-insulin antibodies may develop but are rarely clinically significant. Biosimilar studies have confirmed comparable immunogenicity profiles between reference NovoLog and biosimilar insulin aspart products [13]. The approval of Kirsty (July 2025) as the first interchangeable rapid-acting insulin biosimilar allows pharmacists to substitute it for NovoLog without prescriber intervention, further expanding patient access and reducing costs.

Allergic reactions. Rare systemic allergic reactions (anaphylaxis, generalized urticaria, angioedema) have been reported. Cross-reactivity between insulin analogs is variable, and patients with systemic reactions to one analog may tolerate another.

Hypokalemia. Insulin promotes intracellular potassium uptake and can cause hypokalemia, particularly at higher doses or when administered intravenously. Potassium monitoring is recommended during IV insulin infusion.

Contraindications. Insulin aspart is contraindicated during episodes of hypoglycemia and in patients with hypersensitivity to insulin aspart or any excipient. Fiasp has the same contraindications plus a warning regarding the niacinamide excipient.

Pregnancy. Insulin aspart is designated Category B and is the rapid-acting analog with the strongest pregnancy safety data, based on the Mathiesen trial demonstrating equivalent perinatal outcomes with fewer maternal hypoglycemia events [5].

7. Pharmacokinetics

Insulin aspart is formulated as zinc-stabilized hexamers for shelf stability. Upon subcutaneous injection, the Asp-B28 substitution destabilizes monomer-monomer contacts at the dimer-forming interface, accelerating hexamer dissociation into bioactive monomers within minutes rather than the approximately 30 minutes required for regular human insulin [1][2].

Absorption. Onset of appearance in plasma is approximately 10-20 minutes (NovoLog) or 5-7 minutes (Fiasp, due to niacinamide-enhanced local vasodilation). Fiasp achieves approximately 50% greater insulin exposure in the first 30 minutes and reaches peak concentration approximately 10 minutes earlier than standard aspart [11]. Subcutaneous bioavailability is approximately 60-70%, with absorption fastest from the abdominal site and slowest from the thigh.

Distribution. Volume of distribution is approximately 0.12-0.15 L/kg, similar to endogenous insulin. Insulin aspart does not meaningfully bind to plasma proteins other than the insulin receptor and IGF-1 receptor. Distribution is primarily to extracellular fluid.

Metabolism. Degraded by insulin-degrading enzyme (IDE) primarily in the liver (approximately 60%) and kidney (approximately 35-40%), with identical metabolic pathways to native human insulin. No active metabolites are produced [18].

Elimination. Terminal half-life is approximately 81 minutes (subcutaneous). Duration of glucose-lowering action is 3-5 hours (NovoLog) versus 6-8 hours for regular insulin, reducing late postprandial hypoglycemia risk. Clearance is approximately 1.2 L/h/kg. The pharmacokinetic profile is not significantly altered in mild-to-moderate renal impairment, though insulin requirements often decrease in advanced renal failure due to reduced insulin clearance.

Special populations. Pediatric patients show similar PK/PD profiles to adults. In pregnancy, insulin requirements typically increase in the second and third trimesters. Hepatic impairment may reduce insulin clearance and prolong action.

8. Dose-Response Relationship

Insulin aspart demonstrates a well-characterized dose-response relationship governed by the mealtime carbohydrate load, individual insulin sensitivity, and injection timing relative to meals.

Carbohydrate ratio titration. The standard starting carbohydrate ratio is 1 unit per 10-15 g of carbohydrate, adjusted based on postprandial glucose monitoring. More insulin-resistant patients (typically T2D) may require 1 unit per 5-8 g, while insulin-sensitive patients (lean T1D, children) may need 1 unit per 15-30 g [18].

Correction factor (insulin sensitivity factor). Typically estimated by the "1800 rule" (1800 / total daily dose = expected glucose drop per unit in mg/dL). The correction dose is titrated based on pre-meal glucose to target range.

Dose-dependent postprandial glucose control. In the Cochrane meta-analysis, rapid-acting analogs provided a consistent approximately 0.1% HbA1c reduction over regular insulin across dose ranges, with the postprandial glucose benefit most pronounced at higher carbohydrate loads where the timing mismatch with regular insulin is greatest [12].

Fiasp dose-response. The faster pharmacokinetic profile of Fiasp provides superior 1-hour postprandial glucose control (ETD -12.0 mg/dL in onset 1, -10.9 mg/dL in onset 2) at equivalent unit dosing to standard aspart, with the benefit most apparent at the first hour post-meal where regular aspart has not yet reached peak activity [7][8].

Injection timing optimization. Pre-meal injection 15-20 minutes before eating provides optimal glucose matching with standard aspart. Fiasp allows injection at the start of or up to 20 minutes after starting the meal without loss of postprandial control [19].

9. Comparative Effectiveness

Insulin aspart vs insulin lispro. Head-to-head studies and the Cochrane meta-analysis show no clinically significant differences in HbA1c reduction, postprandial glucose control, hypoglycemia rates, or patient satisfaction between aspart and lispro. Both have identical onset (10-20 min), similar peak (1-3 h), and comparable duration (3-5 h). The analogs are considered clinically interchangeable by major guidelines [10][12].

Insulin aspart vs insulin glulisine. Glulisine (Lys-B3/Glu-B29 substitution, zinc-free formulation) has marginally faster initial absorption in some clamp studies but no clinically meaningful differences in glycemic outcomes, hypoglycemia, or weight change versus aspart in head-to-head trials [12].

Fiasp vs standard aspart. The onset trials consistently demonstrated Fiasp's superiority for 1-hour and 2-hour postprandial glucose control (ETD approximately -10 to -13 mg/dL) at equivalent HbA1c. Fiasp offers greater dosing flexibility (injection up to 20 min post-meal). Injection-site reactions are modestly higher with Fiasp (2.9% vs 0.9%) [7][8][9][10].

Fiasp vs Lyumjev (ultra-rapid lispro). No published head-to-head trials exist. Both achieve approximately 3-5 minutes earlier onset than their standard formulations through different excipient strategies (niacinamide for Fiasp; treprostinil plus citrate for Lyumjev). Phase 3 data suggest comparable postprandial glucose improvements (Fiasp ETD -12.0 mg/dL in onset 1; Lyumjev ETD -15.4 mg/dL in PRONTO-T1D), though cross-trial comparison is limited.

Rapid analogs vs regular human insulin. Rapid-acting analogs provide modest but consistent HbA1c improvement (approximately -0.1%), clinically meaningful postprandial glucose reductions (approximately -19 mg/dL), greater dosing convenience (inject at meal vs 30 min before), and no increase in severe hypoglycemia. Benefits are most pronounced in T1D on intensive therapy [3][12].

10. Enhanced Safety Profile

Hypoglycemia risk stratification. Overall hypoglycemia rates with insulin aspart are comparable to regular human insulin in clinical trials. However, the shorter duration of action (3-5 h vs 6-8 h) reduces the risk of late postprandial hypoglycemia (3-6 hours post-meal), which is a common problem with regular insulin, particularly before lunch and during the night. In the pregnancy trial, severe hypoglycemia was 58% lower with aspart (RR 0.42, p=0.005) [5].

Renal impairment. Insulin requirements often decrease in moderate-to-severe renal impairment (eGFR less than 30 mL/min) due to reduced insulin clearance. More frequent glucose monitoring and dose reduction are recommended. No formal dose adjustment guidelines exist, but a 25-50% total daily insulin dose reduction is commonly needed in advanced CKD [18].

Hepatic impairment. Hepatic metabolism accounts for approximately 60% of insulin clearance. In liver disease, reduced insulin clearance may prolong action and increase hypoglycemia risk. Dose reduction and intensified monitoring are recommended.

Pregnancy and lactation. Insulin aspart (Category B) has the strongest pregnancy RCT evidence among rapid-acting analogs (Mathiesen trial, n=322). No adverse perinatal outcomes, and 58% lower severe hypoglycemia versus human insulin. Insulin requirements typically increase in the second/third trimesters and drop rapidly postpartum. Compatible with breastfeeding [5].

Pediatric use. Confirmed safe and effective in children ages 1-17 years in onset 5 pediatric trial (n=777). Same injection-site rotation and hypoglycemia monitoring principles apply. Children under 2 years have limited data but are commonly treated off-label [10].

Drug interactions. Increased hypoglycemia risk with sulfonylureas, ACE inhibitors, MAO inhibitors, fibrates, and salicylates. Reduced glucose-lowering with corticosteroids, thiazide diuretics, sympathomimetics, and atypical antipsychotics. Beta-blockers may mask hypoglycemia symptoms.

Immunogenicity. Anti-insulin antibodies develop in some patients but are rarely clinically significant. Biosimilar studies (KIXELLE) confirmed comparable immunogenicity to reference NovoLog [13].

Lipodystrophy prevention. Injection-site rotation within and between anatomical regions is essential. Lipohypertrophy at overused sites can lead to erratic absorption and unexplained glycemic variability.

11. Related Peptides

See also: Insulin Lispro (Humalog), Insulin Glargine (Lantus / Toujeo), Insulin Degludec (Tresiba), Pramlintide (Symlin), Semaglutide (Ozempic / Wegovy)

12. References

1. [1] Brange J, Ribel U, Hansen JF, et al. (1988). Monomeric insulins obtained by protein engineering and their medical implications. Nature. DOI PubMed
2. [2] Mudaliar SR, Lindberg FA, Joyce M, et al. (1999). Insulin aspart (B28 asp-insulin) -- a fast-acting analog of human insulin -- absorption kinetics and action profile compared with regular human insulin in healthy nondiabetic subjects. Diabetes Care. DOI PubMed
3. [3] Home PD, Lindholm A, Riis A, et al. (2000). Insulin aspart vs human insulin in the management of long-term blood glucose control in type 1 diabetes mellitus -- a randomized controlled trial. Diabet Med. DOI PubMed
4. [4] Bretzel RG, Arnolds S, Medding J, et al. (2004). A direct efficacy and safety comparison of insulin aspart, human soluble insulin, and human premix insulin (70/30) in patients with type 2 diabetes. Diabetes Care. DOI PubMed
5. [5] Mathiesen ER, Kinsley B, Amiel SA, et al. (2007). Maternal glycemic control and hypoglycemia in type 1 diabetic pregnancy -- a randomized trial of insulin aspart versus human insulin in 322 pregnant women. Diabetes Care. DOI PubMed
6. [6] Bode BW, Weinstein R, Bell D, et al. (2002). Comparison of insulin aspart with buffered regular insulin and insulin lispro in continuous subcutaneous insulin infusion -- a randomized study in type 1 diabetes. Diabetes Care. DOI PubMed
7. [7] Russell-Jones D, Bode BW, De Block C, et al. (2017). Fast-acting insulin aspart improves glycemic control in basal-bolus treatment for type 1 diabetes -- results of a 26-week multicenter, active-controlled, treat-to-target, randomized, parallel-group trial (onset 1). Diabetes Care. DOI PubMed
8. [8] Bowering K, Case C, Harvey J, et al. (2017). Faster aspart versus insulin aspart as part of a basal-bolus regimen in inadequately controlled type 2 diabetes -- the onset 2 trial. Diabetes Care. DOI PubMed
9. [9] Klonoff DC, Evans ML, Lane W, et al. (2019). A randomized, multicentre trial evaluating the efficacy and safety of fast-acting insulin aspart in continuous subcutaneous insulin infusion in adults with type 1 diabetes (onset 5). Diabetes Obes Metab. DOI PubMed
10. [10] Buse JB, Carlson AL, Komatsu M, et al. (2019). Fast-acting insulin aspart versus insulin aspart in the setting of insulin degludec-treated type 1 diabetes -- efficacy and safety from a randomized double-blind trial (onset 5 pediatric). Diabetes Care. DOI PubMed
11. [11] Heise T, Pieber TR, Gianpiero M, et al. (2015). A pooled analysis of clinical pharmacology trials investigating the pharmacokinetic and pharmacodynamic characteristics of fast-acting insulin aspart in adults with type 1 diabetes. Clin Pharmacokinet. DOI PubMed
12. [12] Siebenhofer A, Plank J, Berghold A, et al. (2006). Short acting insulin analogues versus regular human insulin in patients with diabetes mellitus (Cochrane Review). Cochrane Database Syst Rev. DOI PubMed
13. [13] Dreyer M, Garg SK, Engel SS, et al. (2023). Efficacy, safety, and immunogenicity of insulin aspart biosimilar SAR341402 versus NovoLog in adults with type 1 diabetes. Diabetes Care. DOI PubMed
14. [14] Howey DC, Bowsher RR, Brunelle RL, et al. (1994). [Lys(B28), Pro(B29)]-human insulin -- a rapidly absorbed analogue of human insulin. Diabetes. DOI PubMed
15. [15] Hirsch IB. (2005). Insulin analogues. N Engl J Med. DOI PubMed
16. [16] Heinemann L, Flemming R, Gianpiero M, et al. (2000). Time-action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo. Diabetes Care. DOI PubMed
17. [17] Kurtzhals P, Schaffer L, Sorensen A, et al. (2000). Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use. Diabetes. DOI PubMed
18. [18] Novo Nordisk. (2023). NovoLog (insulin aspart injection) -- FDA prescribing information. FDA Label. PubMed
19. [19] Novo Nordisk. (2023). Fiasp (insulin aspart injection) -- FDA prescribing information. FDA Label. PubMed
20. [20] Havelund S, Plum A, Ribel U, et al. (2004). The mechanism of protraction of insulin detemir, a long-acting, acylated analog of human insulin. Pharm Res. DOI PubMed